Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Janux Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
3.64
8.61
8.08
10.6
10
Research and development
3.04
26.2
53.4
54.9
68.4
126
General and administrative
1.8
10.3
22.3
26.1
41
41.8
Operating income
-4.84
-32.9
-67.1
-73
-98.8
-158
Other non-operating income
-1.94
0.26
4.03
14.7
29.9
44
Income tax
0
0
0
Net income
-6.78
-32.7
-63.1
-58.3
-69
-114
EBITDA
-4.83
-32.8
-66.3
-71
-96.8
-156
EPS, basic
-7.41
-1.39
-1.52
-1.32
-1.28
-1.83
EPS, diluted
-7.41
-1.39
-1.52
-1.32
-1.28
-1.83
Shares, basic (weighted)
0.23
23.5
41.5
44
53.8
62
Shares, diluted (weighted)
0.92
23.5
41.5
44
53.8
62
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
7.81
35.6
51.4
19.2
431
52.3
Short-term investments
0
339
276
325
595
914
Receivables
8
0
0
0
0
Other current assets
0.25
2.05
5.42
5.21
8.49
9.32
Total current assets
16.1
377
332
349
1,034
976
Property, plant and equipment
0.16
1.41
7.09
7
4.86
3.85
Lease right-of-use assets
0
0.19
22.3
20.8
19.3
18.4
Other non-current assets
0
0.39
1.39
2.51
2.88
2.61
Total assets
16.2
380
364
380
1,062
1,002
Accounts payable
0.43
2.46
2.16
2.42
4.03
4.97
Accrued liabilities
0.75
3.78
8.18
7.39
11.7
17.6
Deferred revenue
1.95
5.16
5.41
1.71
0
0
Total current liabilities
3.18
12.8
16.5
13
17.5
25
Lease liabilities
0
0
24.5
23
21.3
19.7
Total liabilities
9.23
13.5
43.3
36.1
38.7
44.7
Paid-in capital
0.1
414
433
512
1,258
1,304
Retained earnings
-14.7
-47.4
-110
-169
-238
-351
Other comprehensive income
0
-0.27
-1.54
0.67
2.16
4.32
Shareholders' equity
-14.6
366
321
344
1,023
957
Total equity
-14.6
366
321
344
1,023
957
Total liabilities and equity
16.2
380
364
380
1,062
1,002
Shares outstanding
1.05
41.2
41.6
46.3
59.1
60.4
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-6.78
-32.7
-63.1
-58.3
-69
-114
Depreciation and amortization
0.01
0.11
0.84
1.96
2.06
2.03
Stock-based compensation
0.07
6.91
17.2
20
33
40.2
Deferred income tax
0
0
0
0
0
Change in receivables
-8
8
0
Change in payables
0.01
2.14
-0.29
0.28
1.58
0.98
Cash from operations
-4.37
-17
-42.9
-50.6
-43.8
-82.2
Capital expenditures
0
-1.48
-6.45
-1.85
-0.36
-1.04
Purchases of investments
0
-474
-294
-317
-471
-705
Cash from investing
0
-341
58.3
-41.2
-258
-301
Cash from financing
11.5
387
0.5
59.5
713
4.95
Net change in cash
7.16
28.6
15.8
-32.2
411
-378
Free cash flow
-4.37
-18.5
-49.4
-52.4
-44.2
-83.3
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $16.30 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-598.1%
Operating income / revenue.
EBITDA margin
-590.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-427.5%
Net income / revenue.
FCF margin
-174.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-171.9%
Cash from operations / revenue.
Return on equity (ROE)
-11.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-10.2%
Net income / average total assets.
Return on invested capital (ROIC)
-12.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
516.6%
Research and development expense / revenue.
Stock-based pay / revenue
153.7%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.8%
Capital expenditures / revenue.
D&A / revenue
7.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-5.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
5.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-6.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
44.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-5.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
40.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
128.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
15.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
14.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
132.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
16.3x
Current assets / current liabilities.
Quick ratio
16.1x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
16.1x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.38
Revenue / diluted weighted shares.
FCF per share
-$0.67
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.66
Cash from operations / diluted weighted shares.
Book value per share
$15.19
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
41.5x
Market cap / revenue.
P/B
1.07x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.07x
Market cap / tangible book value, when positive.
EV/Sales
1.07x
Enterprise value / revenue.
FCF yield
-4.2%
Free cash flow / market cap.
Earnings yield
-10.3%
Net income / market cap (the inverse of P/E).
What was Janux Therapeutics, Inc.'s revenue in fiscal 2025?
Janux Therapeutics, Inc. reported revenue of $10.0M for fiscal 2025, 5.6% lower than the year before.
Was Janux Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $113.6M.
How much free cash flow did Janux Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $82.2M minus capital expenditures of $1.0M left free cash flow of -$83.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.